Document is current

Article History

Received: 25 October 2023

Revised: 25 October 2023

Accepted: 28 January 2024

First Online: 24 February 2024

Declarations

:

: AGOL is the current President of the Pacific Dermatology Association and serves as an associate editor for Dermatology (Karger). Additionally, he is a consultant for Genentech and Guidepoint and an advisor to Bristol Meyer Squibb, Boehringer Ingelheim and Janssen. Dr. Ortega has received research grants from the Lilly, Janssen, Incyte and Pfizer. He is supported by NIH NIAMS R01 AR083110. AVM reports consultancy/advisory boards disease-relevant honoraria from AbbVie, Boehringer-Ingelheim, Novartis, Pfizer, Sanofi, Janssen and UCB. VD reports consultancy with Abbvie, Novartis, Eli Lilly, Almirall, UCB, Sanofi, Jansenn. JD reports consultancy/advisory boards disease-relevant honoraria from Boehringer-Ingelheim, InflaRx, Novartis, Janssen and UCB. AAN declares being a consultant and advisor and/or receiving speaking fees/grants and/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, Sanofi, Serono and UCB. YT reports research grants, honoraria from Eisai, Abbvie and Novartis. AA is the board member of HS foundation and a consultant for Abbvie, Almirall, BI, Kymera, InflaRx, Incyte, Novartis, UCB. All other authors declare no competing interests.

: AGOL is the current President of the Pacific Dermatology Association and serves as an associate editor for <i>Dermatology (Karger)</i>. In addition, he is a consultant for Genentech and Guidepoint and an advisor to Bristol Meyer Squibb, Boehringer Ingelheim and Janssen. Dr. Ortega has received research grants from the Lilly, Janssen, Incyte, and Pfizer. He is supported by NIH NIAMS R01 AR083110. AVM reports consultancy/advisory boards disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, Janssen and UCB. VD reports consultancy with Abbvie, Novartis, Eli Lilly, Almirall, UCB, Sanofi, Jansenn. JD reports consultancy/advisory boards disease-relevant honoraria from Boehringer Ingelheim, InflaRx, Novartis, Janssen, and UCB. AAN declares being a consultant and advisor and/or receiving speaking fees/grants and/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, Sanofi, Serono, and UCB. YT reports research grants, honoraria from Eisai, Abbvie and Novartis. AA is the board member of HS foundation and a consultant for Abbvie, Almirall, BI, Kymera, InflaRx, Incyte, Novartis, UCB. All other authors declare no competing interests.